Odyssean LLC Acquires Shares of 124,498 ADMA Biologics Inc $ADMA

Odyssean LLC acquired a new position in shares of ADMA Biologics Inc (NASDAQ:ADMA) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 124,498 shares of the biotechnology company’s stock, valued at approximately $1,042,000.

Other institutional investors and hedge funds also recently modified their holdings of the company. BlackRock Inc. acquired a new stake in shares of ADMA Biologics in the second quarter valued at about $321,037,000. Janus Henderson Group PLC lifted its position in ADMA Biologics by 3,906.1% during the 4th quarter. Janus Henderson Group PLC now owns 3,936,419 shares of the biotechnology company’s stock worth $71,820,000 after acquiring an additional 3,838,158 shares in the last quarter. Capital Research Global Investors boosted its holdings in ADMA Biologics by 104.0% in the 4th quarter. Capital Research Global Investors now owns 6,637,472 shares of the biotechnology company’s stock worth $121,067,000 after acquiring an additional 3,383,559 shares during the period. Caligan Partners LP purchased a new position in ADMA Biologics in the 3rd quarter worth approximately $38,653,000. Finally, Sachem Head Capital Management LP boosted its stake in shares of ADMA Biologics by 27.0% in the fourth quarter. Sachem Head Capital Management LP now owns 11,375,000 shares of the biotechnology company’s stock valued at $207,480,000 after purchasing an additional 2,415,000 shares during the period. Hedge funds and other institutional investors own 75.68% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the stock. Raymond James Financial assumed coverage on shares of ADMA Biologics in a report on Wednesday, June 10th. They set an “outperform” rating and a $21.00 price target for the company. Mizuho decreased their price objective on shares of ADMA Biologics from $20.00 to $17.00 and set an “outperform” rating for the company in a research report on Wednesday, July 15th. Zacks Research upgraded ADMA Biologics from a “strong sell” rating to a “hold” rating in a research note on Wednesday. Finally, Weiss Ratings restated a “hold (c)” rating on shares of ADMA Biologics in a research note on Thursday, June 18th. Three investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $18.67.

ADMA Biologics Trading Up 0.4%

NASDAQ ADMA opened at $9.62 on Friday. The company has a market capitalization of $2.15 billion, a price-to-earnings ratio of 13.74 and a beta of 0.78. The company has a debt-to-equity ratio of 0.49, a current ratio of 6.97 and a quick ratio of 3.81. ADMA Biologics Inc has a 12 month low of $7.21 and a 12 month high of $20.46. The company’s fifty day moving average price is $9.15 and its two-hundred day moving average price is $10.31.

ADMA Biologics (NASDAQ:ADMA) last issued its earnings results on Wednesday, August 5th. The biotechnology company reported $0.16 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.16. ADMA Biologics had a net margin of 32.98% and a return on equity of 40.17%. The business had revenue of $124.39 million for the quarter, compared to analyst estimates of $125.34 million. During the same quarter in the prior year, the business posted $0.14 EPS. The company’s revenue for the quarter was up 2.0% on a year-over-year basis. As a group, research analysts predict that ADMA Biologics Inc will post 0.78 earnings per share for the current fiscal year.

ADMA Biologics Company Profile

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.